SOMA AND “NEW TERRITORIES” PARKING EXPANSION: A PRACTICAL SOLUTION TO MITIGATING SAN FRANCISCO’S PARKING CRISIS A Position Paper and Proposed Solutions Overview – San Francisco’s booming economy has spurred a remarkable surge in commercial renewaland development, bringing with it many new jobs to satisfy increased business andconsumer demand for local products and se
Microsoft word - liraglutideLiraglutide Is an Efficacious Treatment for Type 2
Main Bullet points:
Liraglutide is a glucagon-like-peptide-1 (GLP-1) receptor agonist.
As a once daily injection, Liraglutide has proven to be effectual at lowering blood sugar and
inducing weight loss in patients.
51% of patients who receive the 1.8 milligram doses of Liraglutide reached a target HbA1c
level of less than 7.0%, which is the American Diabetes Association target HbA1c level.
Type 2 Diabetes mellitus affects approximately 24 million people in the United States, and it
is the leading cause of kidney failure and blindness.
Numbers of people with type 2 diabetes are expected to increase worldwide due to the
On January 25, 2010, the FDA approved Liraglutide, a glucagon-like-peptide-1 (GLP-1) receptor agonist, designed to be taken once daily to improve glycemic control in adults with type 2 diabetes. As an analog of a hormone called GLP-1, Liraglutide stimulates insulin secretion and expands the insulin-making beta cells in the pancreas. Liraglutide is a once daily injection, and has shown itself to be effectual at not only lowering blood sugar in patients, but also helpful for weight loss, which is often an issue for patients with type 2 diabetes. Side effects of Liraglutide include nausea, vomiting, and diarrhea, but they have typically been apparent for the first month of treatment only, in recorded studies. The main potential downside to Liraglutide is that as a DPP-4 inhibitor it plays a role in the immunity of patients, similar to other DPP-4 medications, thus giving patients a slightly an increased risk of infections. In a study conducted by Baylor College of Medicine lead by researcher Alan Garber, MD, PhD, and colleagues, Liraglutide was compared to Amaryl, another medication developed to stimulate insulin secretion. This study involved 746 patients with early type 2 diabetes. Participants received a once-daily dose of 1.2 milligrams or 1.8 milligrams of Liraglutide, via injection, or a comparable once daily oral dose of Amaryl. In addition, patients who received Liraglutide were also given placebo pills, and those participants who were dosed with Amaryl received injections of a harmless, inactive 2012 All rights reserved by Yes Pharma Ltd. Placebo. The HbA1c scores (a measure of long-term blood-sugar control) of patients in the study was initially measured and ranged from 7% to 11%. After a total of 52 weeks of treatment patients who received 1.8 milligrams of Liraglutide showed a 1.14% drop in their HbA1c scores. HbA1c scores dropped 0.84% in patients who received 1.2 milligram doses of Liraglutide. In comparison, the patients who were dosed with Amaryl showed a less significant drop of 0.51% in their HbA1c scores. Additionally, an encouraging 51% of patients who received the 1.8 milligram doses of Liraglutide reached a target HbA1c level of less than 7.0%, which is the American Diabetes Association target HbA1c level. A healthy 43% of patients who were dosed with 1.2 milligrams of Liraglutide reached the ADA target HbA1c level. Only 28% of patients who were dosed with Amaryl reached the ADA target HbA1c level. Another enlightening result from this study was that the patients who received Liraglutide actually lost weight, while many of the patients treated with Amaryl gained weight. The patient weight loss, which was recorded over the first 16 weeks of the study, was also documented as being maintained by patients at the one-year mark of this trial. One more bonus of Liraglutide was that patients who were dosed with this phenomenal drug had a reduced blood pressure, even greater than the reduction that Amaryl elicited. Type 2 diabetes mellitus affects approximately 24 million people in the United States, and it is the leading cause of kidney failure and blindness. Shockingly, type 2 diabetes is also associated with almost a quadrupling of the risk of death for patients from cardiovascular causes. With the numbers of people with type 2 diabetes expected to increase worldwide due to the obesity epidemic, innovative, safe and efficacious treatments are greatly needed. For researchers, practitioners and patients concerned with the possibility of pancreatitis amongst those people dosed with Liraglutide long-term, the incidence of this condition has been minimal. In both the phase 2 and phase 3 trials of Liraglutide, there were seven total cases of pancreatitis reported out of 4, 257 patients treated with Liraglutide. Prescribers and patients are advised to note persistent or severe nausea and vomiting, as these symptoms could potentially be early manifestations of pancreatitis. The advent of tolerable and effectual medications to treat patients with type 2 diabetes is a must for the current generation of patients worldwide who are struggling with obesity and glycemic control issues. Liraglutide is an anti-diabetes medication that shows promise not only for the present, but also for the future. 2012 All rights reserved by Yes Pharma Ltd.
YES Pharma is proud to be a leading supply source for Liraglutide (CAS#: 204656-20-2)
to several global pharmaceutical companies and academic research institutes, while
recognizing that we play a significant part in promoting the struggle against Type 2
Diabetes. The Liraglutide that YES Pharma supplies is intended for laboratory R&D use
The Lancet September 25, 2008 Mary Parks, M.D., and Curtis Rosebraugh, M.D., M.P.H. N Engl J Med 2010; 362:774-777 March 4, 2010 From the Division of Metabolism and Endocrinology Products (M.P.) and the Office of Drug Evaluation II (C.R.), Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD. Products covered by valid patents are not offered or supplied for commercial use. Products currently covered by valid US patents are offered only for laboratory R&D use in accordance with 35 USC 271(e)+A13(1). • Any patent infringement and resulting liability is solely at buyer risk. 2012 All rights reserved by Yes Pharma Ltd.
DITROPAN XL Flash E-Mail Impactful Openers 1. Overactive bladder dysfunction is estimated to affect over 33 million patients in the United States. In your practice, how many patients do you see weekly that suffer from symptoms of urgency, frequency and/ -or urge urinary incontinence? 2. Doctor, last time I was here, you explained to me that efficacy and tolerability are the most imp